HPV vaccines for circumpolar health: summary of plenary session, “Opportunities for Prevention: Global HPV Vaccine” and “Human Papillomavirus Prevention: The Nordic Experience”

Figures & data

Table I HPV vaccines

	Quadrivalent (Gardasil)	Bivalent (Cervarix)
Manufacturer	Merck	GlaxoSmithKline
VLP types	6, 11, 16 and 18	16 and 18
Dose of protein	20/40/40/20 µg	20/20 µg
Producer cells	Saccharomyces cerevisiae (yeast)	Baculovirus-infected Trichoplusiani insect cell line
Adjuvant	AAHS:	AS04:
	225 µg amorphous aluminum hydroxyphosphate sulphate	500 µg aluminum hydroxide 50 µg 3-O-desacyl-4′-monophosphoryl lipid A
Schedule (IM)	3 dose series	3 dose series

Abbreviations: VLP, virus-like particle; IM, intramuscular.

Table II Summary of HPV vaccine programmes in the Nordic countries

	Start year	Target ages (years)	Administration	Vaccine	Cost through public programme	Vaccine register
Denmark	R: 2009	R: 12	Medical Home	Gardasil	Free	Planned
	C: 2008	C: 13–15 +20–28
Greenland	R: 2008	R: 12	Mixed	Gardasil	Free	Partly
	C: 2009	C: 13–15
Norway	R: 2009	R: 12	School	Gardasil	Free	Yes
Iceland	R, C: 2011–2012	R: 12	School	Cervarix	Free	Yes
		C: 13
Sweden	R: 2011	R: 11–12	School	Gardasil	R: Free	Yes
Finland	Not decided	–	–	–	–	–

R, routine; C, catch up.

Source: Reference 10.